(UroToday.com) In the on-demand poster session of the European Society for Medical Oncology (ESMO) Annual Congress, Dr. Christopher Darr presented results of the phase II NIVOSWITCH trial assessing whether a 1st line switch-maintenance approach (CPI after TKI) improved outcome in metastatic clear cell renal cell carcinoma (mRCC). Each of these treatment approaches (CP and TKI) are accepted standards of care.